XORTX Therapeutics

Historical price data

XORTX Therapeutics is a clinical-stage biotech focused on developing treatments for progressive kidney diseases driven by elevated uric acid. Its core achievement is advancing oxypurinol, a xanthine oxidase inhibitor, into a pivotal Phase 3 trial (XRX-OXY-301) for ADPKD, a condition with no approved disease-modifying therapies. The company's strategy leverages established drug safety to de-risk development while targeting a significant unmet medical need. Success in its Phase 3 trial would validate its scientific hypothesis and create substantial value.

A therapeutic hypothesis and development platform centered on inhibiting xanthine oxidase to lower pathogenic uric acid levels, aiming to slow progression in specific kidney diseases like ADPKD and diabetic nephropathy.

In ADPKD, primary competition is tolvaptan; oxypurinol differentiates on mechanism and potential safety. In diabetic kidney disease, the landscape is dominated by SGLT2 inhibitors and GLP-1s, creating a high bar for new entrants like XRX-008.